Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Date: November 21, 2023 (Report Date)
Event Date: November 21, 2023
Context: The filing reports a significant contract modification with the U.S. Department of Health and Human Services regarding the procurement of the anthrax vaccine CYFENDUS.
Key Financial Metrics
This Form 8-K does not contain comprehensive financial statements (revenue, profit, cash flow, or margins) for a reporting period. The only specific financial figure disclosed is:
- Contract Value: $75 million for the procurement of additional doses of CYFENDUS.
Material Changes
The primary material event is the exercise of "Modification No. 16" under the BARDA AV7909 Contract. This modification secures funding for the procurement of additional doses of the newly licensed CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). This represents a continuation and expansion of the existing development and procurement agreement originally effective September 30, 2016.
Outlook and Management Commentary
- Delivery Timeline: Deliveries of CYFENDUS are expected to begin in the current calendar year (2023) and be completed by the end of the first quarter of 2024.
- Documentation: The full text of Modification No. 16 is expected to be filed as an exhibit to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
- Risks/Contingencies: The filing notes that the description of the modification is qualified by reference to the full text of the agreement, which contains redactions for confidential information.
Investor Verification Checklist
- Verify the exact delivery schedule and payment terms within the full text of Modification No. 16 once filed in the 2023 Form 10-K.
- Confirm the impact of the $75 million contract on the company's 2023 and 2024 revenue recognition schedules.
- Review the press release (Exhibit 99.1) for additional details on production capacity and regulatory status.
- Monitor future filings for any changes to the delivery timeline or contract value.